Black­stone's GRIN inks epilep­sy li­cens­ing deal with An­geli­ni, clos­es $140M Se­ries D

Ital­ian drug­mak­er An­geli­ni Phar­ma is set to help GRIN Ther­a­peu­tics take its neu­rode­vel­op­men­tal dis­or­der med­i­cine to re­gions out­side North Amer­i­ca.

An­geli­ni will pay $50 mil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER